

CLAIMS


1. Use of a compound in the manufacture of a medicament ~~A method~~ for treating an RNA viral infection in a human, wherein the compound is ~~comprising administering a therapeutically effective amount of a compound having a structure of Formula (I):~~



Compound A, or



Compound B;



~~wherein:~~

~~A is a saturated or partially saturated optionally substituted 5, 6 or 7 membered ring;~~

~~—— represents a single bond or a double bond;~~

~~Z^1 and Z^2 are independently N or C when —— represents a single bond, provided Z^1 and~~

Z^2 are not both N; and

Z^1 and Z^2 are C when ---- represents a double bond;

L is a linker selected from a bond, NR^3, O, S, CR^4R^5, CR^4R^5-NR^3, CR^4R^5-O-, and CR^4R^5-S; each R^1, R^2, R^3, R^4 and R^5 is independently H, or an optionally substituted member selected from the group consisting of C1-C8 alkyl, C2-C8 heteroalkyl, C2-C8 alkenyl, C2-C8 heteroalkenyl, C2-C8 alkynyl, C2-C8 heteroalkynyl, C1-C8 acyl, C2-C8 heteroacyl, C6-C10 aryl, C5-C12 heteroaryl, C7-C12 arylalkyl, and C6-C12 heteroarylalkyl group, or halo, OR, NR_2, NROR, $NRNR_2$, SR, SOR, SO_2R, SO_2NR_2, $NRSO_2R$, $NRCONR_2$, $NRCSNR_2$, $NRC(=NR)NR_2$, NRCOOR, NRCOR, CN, COOR, $CONR_2$, OOCR, COR, or NO_2, wherein each R is independently H or C1-C8 alkyl, C2-C8 heteroalkyl, C2-C8 alkenyl, C2-C8 heteroalkenyl, C2-C8 alkynyl, C2-C8 heteroalkynyl, C1-C8 acyl, C2-C8 heteroacyl, C6-C10 aryl, C5-C10 heteroaryl, C7-C12 arylalkyl, or C6-C12 heteroarylalkyl,

and wherein two R on the same atom or on adjacent atoms can be linked to form a 3-8 membered ring, optionally containing one or more N, O or S;

and each R group, and each ring formed by linking two R groups together, is optionally substituted with one or more substituents selected from halo, =O, =N-CN, =N-OR', =NR', OR', NR'_2, SR', SO_2R', $SO_2NR'_2$, $NR'SO_2R'$, NR'CONR'$_2$, NR'CSNR'$_2$, NR'C(=NR')NR'$_2$, NR'COOR', NR'COR', CN, COOR', CONR'$_2$, OOCR', COR', and NO_2,

wherein each R' is independently H, C1-C6 alkyl, C2-C6 heteroalkyl, C1-C6 acyl, C2-C6 heteroacyl, C6-C10 aryl, C5-C10 heteroaryl, C7-12 arylalkyl, or C6-12 heteroarylalkyl, each of which is optionally substituted with one or more groups selected from halo, C1-C4 alkyl, C1-C4 heteroalkyl, C1-C6 acyl, C1-C6 heteroacyl, hydroxy, amino, and =O; and wherein two R' on the same atom or on adjacent atoms can be linked to form a 3-7 membered ring optionally containing up to three heteroatoms selected from N, O and S; and R^1 can be =O, or two R^1 groups on the same atom or on adjacent connected atoms, can optionally be linked together to form a 3-8 membered cycloalkyl or heterocycloalkyl, which is optionally substituted; and R^4 and R^5, when on the same atom or on adjacent connected atoms, can optionally be linked together to form a 3-8 membered cycloalkyl or heterocycloalkyl, which is optionally substituted;

W is alkyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, arylalkyl or heteroarylalkyl, each of which can be optionally substituted;

X is a polar substituent;

and each m is independently 0-3;

or a pharmaceutically acceptable salt or ester thereof.

2. The method of claim 1, wherein L is NH or NMe.

3. The method of claim 1, wherein W is selected from the group consisting of optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, and optionally substituted heterocyclyl.

4. The method of claim 1, wherein Z^1 and Z^2 are C and ---- represents a double bond.

5. The method of claim 1, wherein Z^1 is N, Z^2 is C and ---- represents a single bond.


6. The method of claim 1, wherein Z^1 is C, Z^2 is N and ---- represents a single bond.


7. The method of claim 1, wherein W is optionally substituted phenyl, optionally substituted heterocyclyl, or C1-C4 alkyl substituted with at least one member selected from the group consisting of optionally substituted phenyl, optionally substituted heteroalkyl, optionally substituted heteroaryl, halo, hydroxy and $-NR"_2$, where each R" is independently H or optionally substituted C1-C6 alkyl; and two R" taken together with the N to which they are attached can be linked together to form an optionally substituted 3-8 membered ring, which can contain another heteroatom selected from N, O and S as a ring member, and can be saturated, unsaturated or aromatic.


8. The method of claim 1, wherein L is NH or NMe.


9. The method of claim 7, wherein W comprises at least one group of the formula $-(CH_2)_p-NR^x_2$, where p is 1-4, R^x is independently at each occurrence H or optionally substituted alkyl; and two R^x taken together with the N to which they are attached can be linked together to form an optionally substituted 3-8 membered ring, which can contain another heteroatom selected from N, O and S as a ring member, and can be saturated, unsaturated or aromatic.


10. The method of claim 1, wherein A is selected from the group consisting of:



,


,





, and


,

wherein Z^3 is CR^1_2, NR^1, $S(=O)_p$, or O; n is 1-3; and p is 0-2.

11. The method of claim 1, wherein X is selected from the group consisting of $COOR^9$, $C(O)NR^9$-OR^9, triazole, tetrazole, CN, imidazole, carboxylate, a carboxylate bioisostere,





wherein each R^9 is independently H or an optionally substituted member selected from the group consisting of alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, arylalkyl, cycloalkylalkyl, heterocycloalkylalkyl, and heteroarylalkyl, and two R^9 on the same or adjacent atoms can optionally be linked together to form an optionally substituted ring that can also contain an additional heteroatom selected from N, O and S as a ring member; R^{10} is halo, CF_3, CN, SR, OR, NR_2, or R, where each R is independently H or optionally substituted C1-C6 alkyl, and two R on the same or adjacent atoms can optionally be linked together to form an optionally substituted ring that can also contain an additional heteroatom selected from N, O and S as a ring member; and B is N or CR^{10}.


12. The method of claim 1, wherein the polar substituent X is located at position 3 on the phenyl ring.


13. The method of claim 1, wherein the polar substituent X is located at position 4 on the phenyl ring.


14. The method of claim 1, wherein -L-W is selected from:














~~wherein each R^a is independently H, Cl or F;~~

each R^b is independently Me, F, or Cl; each R is independently selected from H, halo, C1-C4 alkyl, C1-C4 alkoxy, and

C1-C4 haloalkyl, and two R groups on the same or adjacent connected atoms can optionally be linked together to form a 3-8 membered ring;

each B is N or CR; and each Solgroup is a solubility-enhancing group.

15. A method of claim 1, wherein the compound is one having a structure of Formula (II):



(II)

wherein:

A is a saturated or partially saturated optionally substituted 5, 6 or 7 membered ring;

---- represents a single bond or a double bond;

Z^1 and Z^2 are independently N or C when ---- represents a single bond, provided Z^1 and Z^2 are not both N; and

Z^1 and Z^2 are C when ---- represents a double bond;

each of R^1 and R^2 is independently H, or an optionally substituted member selected from the group consisting of C1-C8 alkyl, C2-C8 heteroalkyl, C2-C8 alkenyl, C2-C8 heteroalkenyl, C2-C8 alkynyl, C2-C8 heteroalkynyl, C1-C8 acyl, C2-C8 heteroacyl, C6-C10 aryl, C5-C12 heteroaryl, C7-C12 arylalkyl, and C6-C12 heteroarylalkyl group, or halo, OR, NR_2, NROR, $NRNR_2$, SR, SOR, SO_2R, SO_2NR_2, $NRSO_2R$, $NRCONR_2$, $NRCSNR_2$, $NRC(=NR)NR_2$, NRCOOR, NRCOR, CN, COOR, $CONR_2$, OOCR, COR, or NO_2,

wherein each R is independently H or C1-C8 alkyl, C2-C8 heteroalkyl, C2-C8 alkenyl, C2-C8 heteroalkenyl, C2-C8 alkynyl, C2-C8 heteroalkynyl, C1-C8 acyl, C2-C8 heteroacyl, C6-C10 aryl, C5-C10 heteroaryl, C7-C12 arylalkyl, or C6-C12 heteroarylalkyl,

and wherein two R on the same atom or on adjacent atoms can be linked to form a 3-8 membered ring, optionally containing one or more N, O or S; and each R group, and each ring formed by linking two R groups together, is optionally substituted with one or more substituents selected from halo, =O, =N-CN, =N-OR', =NR', OR', NR'_2, SR', SO_2R', $SO_2NR'_2$, $NR'SO_2R'$, $NR'CONR'_2$, $NR'CSNR'_2$, $NR'C(=NR')NR'_2$, NR'COOR', NR'COR', CN, COOR', $CONR'_2$,

~~OOCR', COR', and NO_2, wherein each R' is independently H, C1-C6 alkyl, C2-C6 heteroalkyl, C1-C6 acyl, C2-C6 heteroacyl, C6-C10 aryl, C5-C10 heteroaryl, C7-12 arylalkyl, or C6-12 heteroarylalkyl, each of which is optionally substituted with one or more groups selected from halo, C1-C4 alkyl, C1-C4 heteroalkyl, C1-C6 acyl, C1-C6 heteroacyl, hydroxy, amino, and =O; and wherein two R' on the same atom or on adjacent atoms can be linked to form a 3-7 membered ring optionally containing up to three heteroatoms selected from N, O and S; and R^1 can be =O, or two R^1 groups on the same atom or on adjacent connected atoms, can optionally be linked together to form a 3-8 membered cycloalkyl or heterocycloalkyl, which is optionally substituted;~~

~~W is alkyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, arylalkyl or heteroarylalkyl, each of which can be optionally substituted;~~

~~X is a polar substituent;~~

~~and each m is independently 0-3;~~

~~or a pharmaceutically acceptable salt or ester thereof.~~

~~16. The method of claim 15, wherein W is selected from the group consisting of optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, and optionally substituted heterocyclyl.~~

~~17. The method of claim 15, wherein Z^1 and Z^2 are C and ---- represents a double bond.~~

~~18. The method of claim 15, wherein Z^1 is N, Z^2 is C and ---- represents a single bond.~~

~~19. The method of claim 15, wherein Z^1 is C, Z^2 is N and ---- represents a single bond.~~

~~20. The method of claim 15, wherein W is optionally substituted phenyl, optionally substituted heterocyclyl, or C1-C4 alkyl substituted with at least one member selected from the group consisting of optionally substituted phenyl, optionally substituted heteroalkyl, optionally substituted heteroaryl, halo, hydroxy and $-NR"_2$,~~

~~where each R" is independently H or optionally substituted C1-C6 alkyl;~~


~~and two R" taken together with the N to which they are attached can be linked together to form an optionally substituted 3-8 membered ring, which can contain another heteroatom selected from N, O and S as a ring member, and can be saturated, unsaturated or aromatic.~~


~~21. The method of claim 20, wherein W comprises at least one group of the formula $-(CH_2)_p-NR^x_2$, where p is 1-4,~~

~~R^x is independently at each occurrence H or optionally substituted alkyl;~~

~~and two R^x taken together with the N to which they are attached can be linked together to form an optionally substituted 3-8 membered ring, which can contain another heteroatom selected from N, O and S as a ring member, and can be saturated, unsaturated or aromatic.~~


~~22. The method of any one of claims 15, wherein A is selected from the group consisting of:~~





wherein Z^3 is CR^1_2, NR^1, $S(=O)_p$, or O; n is 1-3; and p is 0-2.

23. The method of claim 15, wherein X is selected from the group consisting of $COOR^9$, $C(O)NR^9$-OR^9, triazole, tetrazole, CN, imidazole, carboxylate, a carboxylate bioisostere,



wherein each R^9 is independently H or an optionally substituted member selected from the group consisting of alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, arylalkyl, cycloalkylalkyl, heterocycloalkylalkyl, and heteroarylalkyl,

and two R^9 on the same or adjacent atoms can optionally be linked together to form an optionally substituted ring that can also contain an additional heteroatom selected from N, O and S as a ring member; R^{10} is halo, CF_3, CN, SR, OR, NR_2, or R, where each R is independently H or optionally substituted C1-C6 alkyl, and two R on the same or adjacent


~~atoms can optionally be linked together to form an optionally substituted ring that can also contain an additional heteroatom selected from N, O and S as a ring member;~~

~~and B is N or CR^{10}.~~


~~24. The method of claim 23, wherein the polar substituent X is located at position 3 on the phenyl ring.~~

~~25. The method of claim 23, wherein the polar substituent X is located at position 4 on the phenyl ring.~~


~~26. The method of claim 1, wherein the compound is selected from the group consisting of the following compounds:~~



~~Compound A;~~




~~Compound B; and~~




~~Compound C.~~


~~27~~2. The use ~~method~~ of claim 1, wherein the compound is Compound A having the structure of



~~28. The method of claim 1, wherein the compound is Compound B having the structure of~~



~~29. The method of claim 1, wherein the compound is Compound C having the structure of~~



~~30~~3. The use ~~method~~ of claim 1, wherein the RNA virus is severe acute respiratory syndrome-related coronavirus (SARS-CoV), or SARS-CoV-2.

~~31~~4. The use ~~method~~ of claim 1, wherein the RNA viral infection is COVID-19.

~~32. A pharmaceutical composition for treating an RNA viral infection, comprising a compound set forth in any one of claims 1-29 and a pharmaceutically acceptable excipient.~~

~~33. The pharmaceutical composition of claim 32, wherein the compound is Compound A.~~

~~34. The pharmaceutical composition of claim 32, wherein the compound is Compound B.~~

~~35. The pharmaceutical composition of claim 32, wherein the compound is Compound C.~~

~~36. The pharmaceutical composition of claim 32, wherein the RNA virus is SARS-CoV-2.~~

~~37. The pharmaceutical composition of claim 32, wherein the RNA viral infection is COVID-19.~~

~~38. A use of a compound as described in any one of claims 1-29, or a pharmaceutically acceptable salt or ester thereof, in the preparation of a medicament for treating an RNA viral infection.~~

~~39. The use of claim 38, wherein the RNA viral infection is COVID-19.~~